Table 1.

Lung cancer screening trials published since 2016

TRIAL NAME, COUNTRY	MEDIAN FOLLOW-UP, Y	SAMPLE SIZE, N	CRITERIA	INTERVENTION	LUNG CANCER MORTALITY	ALL-CAUSE MORTALITY
LDCT vs CXR
NLST,^9,10 USA	12.3	53 454	Age 55-74 y ≥ 30 pack-years smoking ≤ 15 y since quitting	3 annual scans	RR = 0.80 (95% CI 0.73-0.93)	RR = 0.97 (95% CI 0.94-1.01)
LDCT vs no screening
NELSON,⁸ the Netherlands and Belgium	> 10	13 195 men, 2594 women	Age 50-74 y ≥ 15 cigarettes/d for ≥ 25 y or ≥ 10 cigarettes/d for ≥ 30 y ≤ 10 y since quitting	4 scans (at 0, 1, 3, and 5.5 y)	RR = 0.76 for men RR = 0.67 for women	NA
MILD,¹¹ Italy	> 10	4099	Age 49-75 y ≥ 20 pack-years smoking ≤ 10 y since quitting	10 annual scans or 5 biennial scans	HR = 0.61 (95% CI 0.39-0.95)	HR = 0.80 (95% CI 0.62-1.03)
LUSI,¹² Germany	8.8	4052	Age 50-69 y ≥ 15 cigarettes/d for ≥ 25 y or ≥ 10 cigarettes/d for ≥30 y ≤ 10 y since quitting	5 annual scans	HR = 0.74 (95% CI 0.46-1.19) HR = 0.94 (95% CI 0.54-1.61) for men HR = 0.31 (95% CI 0.10-0.96) for women	HR = 0.99 (95% CI 0.79-1.25)

CXR—chest x-ray, HR—hazard ratio, LDCT—low-dose computed tomography, LUSI—Lung Cancer Screening Intervention, MILD—Multicentric Italian Lung Detection, NA—not applicable, NELSON—Nederlands–Leuvens Longkanker Screenings Onderzoek, NLST—National Lung Screening Trial, RR—rate ratio, USA—United States of America.